Events

Patent protection for EU funding beneficiaries - Biotechnology
DEC
Tue
10
09:30 - 11:00

This was 1 year ago

Location

Online

Programmes
Health Agro-Food, Environment EIC EIT

This lecture series, co-organised by the European Patent Office (EPO) and the European IP Helpdesk, addresses the IP-related aspects of EU-funded projects. It introduces the main aspects of IP management: notably IP ownership, protection and exploitation.

This edition explores the interface between patents and biotechnology.

On the agenda:

  • Introduction
  • Presentation of main aspects of IP management in EU-funded projects
  • Getting to know patents
  • Patentability of new technological developments in biotechnology
  • Learning resources
  • Q&A


More information and registration on the dedicated webpage.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.